Drug Trial Radar · NCT04964375
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
102
Actual
Start
Aug 31, 2021
Primary completion
Jul 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor. Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043
Conditions
- Neoplasms
Interventions
ABSK043 oral capsuleDrug
ABSK043 is a novel, oral small molecule inhibitor of PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Incidence and Severity of AEsTime frame: Through study completion, an average of 6 months
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
Sydney South West Private Hospital
Liverpool, Australia
Icon Cancer Centre South Brisbane
Brisbane, Queensland, Australia
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Chongqing University Cancer Hospital
Chongqing, China
Fujian Cancer hospital
Fuzhou, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
The Second Hospital of Anhui Medical University
Hefei, China
Mianyang Central Hospital
Mianyang, China
Jiangsu Province Hospital
Nanjing, China
Shanghai Chest Hospital
Shanghai, China
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, China
Yuebei People's Hospital
Shaoguan, China
Liaoning Cancer Hospital
Shenyang, China
Renmin Hospital of Wuhan University
Wuhan, China
Union Hospital Tongji Medical College Huazhong University of science and technology
Wuhan, China
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, China
Xiangyang Central Hospital
Xiangyang, China
Yanbian University Hospital(Yanbian Hospital)
Yanbian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.